CN106518767A — 取代苯并吡唑二芳基脲类化合物,其制备方法及其医药用途
Assigned to Institute of Pharmacology and Toxicology of AMMS · Expires 2017-03-22 · 9y expired
What this patent protects
本发明取代苯并吡唑二芳基脲类化合物,其制备方法及其医药用途涉及通式I化合物,或其异构体、可药用盐及溶剂化物;本发明还涉及包含通式I化合物或其异构体、可药用盐及溶剂化物,以及药学上可接受的载体、赋形剂或稀释剂的组合物;本发明还涉及通式I化合物,或其异构体、可药用盐及溶剂化物,用于克服炎症、炎症相关疾病、肿瘤及窒息性气体或刺激性气体造成的急性肺损伤的用途;特别是用于与P38 MAPK通路有关的疾病或症状中的用途。
USPTO Abstract
本发明取代苯并吡唑二芳基脲类化合物,其制备方法及其医药用途涉及通式I化合物,或其异构体、可药用盐及溶剂化物;本发明还涉及包含通式I化合物或其异构体、可药用盐及溶剂化物,以及药学上可接受的载体、赋形剂或稀释剂的组合物;本发明还涉及通式I化合物,或其异构体、可药用盐及溶剂化物,用于克服炎症、炎症相关疾病、肿瘤及窒息性气体或刺激性气体造成的急性肺损伤的用途;特别是用于与P38 MAPK通路有关的疾病或症状中的用途。
Drugs covered by this patent
- Journavx (SUZETRIGINE) · Vertex Pharms Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.